Kidney function is highly susceptible to age-related changes, with chronic kidney disease (CKD) serving as an important cause of morbidity and mortality in older patients. The prevalence of CKD in Korea is higher among the elderly, relative to the general population, with the most significant increases seen following the onset of menopause. Under normal conditions, estrogen attenuates renal superoxide production and protects the kidney from oxidative damage. As estrogen levels are known to decrease by as much as 80% during menopause, this represents a significant risk for older women. Postmenopausal hormone replacement therapy (HRT) modulates the renin-angiotensin system, thereby reducing the progressive deterioration of renal function. Use of estrogen-based HRT has been shown to ameliorate renal function in postmenopausal women, and delay CKD progression. Renal expression of klotho, an important suppressor of aging, is markedly decreased in CKD patients, making it a promising candidate for use as a prognostic biomarker in CKD. Here, we review the key links between renal function, sex, age, and estrogen levels during menopause, and discuss the use of postmenopausal HRT in CKD attenuation. (J Menopausal Med 2018;24:75-80)
Introduction
Chronic kidney diseases (CKD) are one of the many problems that arise in older populations. The prevalence of CKD increases with age, with significantly higher incidence seen among the elderly (22.0%), relative to both middleaged (6.4%) and young individuals (2.8%). 1 In Korea, the prevalence of CKD varies based on sex and menopausal status, with an incidence of 7.4% in men and 4.7% in premenopausal women, compared to 20.1% in postmenopausal women. 2 Development of CKD is associated with accelerated aging and is closely related with metabolic disorders (MD). Under normal conditions, estrogen attenuates renal pathology;
however, as estrogen levels can decrease by as much as 80% during menopause, 3 this represents a significant risk for older women. It is therefore important to identify ways to preserve kidney function as patients' age.
Estrogen has been shown to protect against both the occurrence and progression of CKD, making it an attractive option for delaying CKD progression. Estrogen-based hormone replacement therapies (HRT) have been shown to confer protective effects on kidney-related diseases by attenuating kidney injuries caused by superoxide production.
Klotho is a well-established anti-aging gene that is highly expressed in the kidneys. Expression of this gene has been shown to inhibit kidney diseases, 4 with significant evidence regarding its role in the pathophysiology of CKD.
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Here, we examined sex-specific differences in renal function and CKD, focusing on the relationship between estrogen levels and menopause in older populations. Furthermore, we review the effects of postmenopausal HRT and klotho expression on the incidence and progression of CKD.
Disease Burden of CKD 1. CKD incidence by sex and age CKD is widely regarded as a disease of aging, with higher incidence seen in elderly populations. According to a nationwide survey, the prevalence of CKD in Korea was 8.2%
among adults aged ≥20 years. 1 Kim et al. 5 reported that the prevalence was 13.7% among for residents aged ≥35 years of age in Korea. The overall incidence of CKD was shown to increase in accordance with age in both sexes, with the most significant changes seen in women aged >50 years. 2 Given the aging population of many countries throughout the world, CKD will represent an important public health concern in the years to come.
Aging and CKD
CKD is associated with accelerated aging due to the accumulation of uremic toxins, oxidative stress, and persistent inflammation. 6 As people grow older, accumulated kidney damage leads to decreases in both the estimated glomerular filtration rate (eGFR) and renal blood flow (RBF). eGFR is typically low at birth and does not reach adult levels until the late 20s, where it is maintained at ~140 mL/min/1.73 m 2 into the 40s, 7 after which levels decline by ~8 mL/ min/1.73 m 2 per decade thereafter. 8, 9 Similarly, RBF levels are maintained at ~600 mL/min into the late 40s, followed by declines of ~10% per decade. clinical significance of these findings.
Sex differences in nitric oxide (NO) production
and kidney disease progression According to the most inclusive meta-analysis to date, comprising a total of 11,345 patients from 68 studies, women are likely to progress to end-stage renal disease (ESRD) more slowly than men. 17 Potential mechanisms for sex differences in kidney disease progression can be explained based on differences in NO metabolism, oxidative stress, sex steroids, lifestyle differences, and other sex-specific risk factors. 16 NO is a potent regulator of vascular tone, with deficiencies in NO synthesis leading to endothelial dysfunction. 18 Within the kidneys, NO has been shown to inhibit the growth of mesangial cells, and limit production of extracellular matrix components. 18 Low NO levels in both blood and urine are generally observed in CKD patients. 19, 20 Schmidt and Baylis 9 demonstrated that total NO production was nearly 9-fold lower in the peritoneal dialysis group (57 ± 26 μmol/24 h) relative to healthy group (525 ± 108 μmol/24 h), while Luksha et al. 18 observed ~2-fold lower total urinary NO excretion in CKD patients (410 ± 56 μmol/24 h) compared to controls (914 ± 129 μmol/24 h).
Sexual dimorphism in the NO system extends beyond humans, having been reported in several animal models of renal disease. These results suggest that sex difference in renal NO production is one of the contributing factors to the progression of renal disease. Ji et al. 21 reported that female rats with renal wrap (RW) hypertension (RWH) have higher NO levels than male rats, and that male rats with RWH are more susceptible to changes in NO production. Endothelial NO synthase (eNOS) production was 2.8-fold higher in the sham-operated female renal cortex compared to males.
Furthermore, RWH had no effect on eNOS and neuronal NO synthase (nNOS) expression in the renal cortex and medulla of female rats, compared with males where eNOS expression was significantly upregulated in both the renal cortex and medulla, while nNOS protein expression was noticeably decreased in the medulla. These results suggest that the kidneys upregulate the expression of eNOS to compensate for the loss in medullary nNOS. A sustained, chronic loss of renal nNOS may therefore lead to hypertension and a decrease in GFR.
In human studies, sex differences in kidney diseases can probably be attributed to estrogen-mediated increases in renal NO synthase production. 22~24 Healthy premenopausal women show greater NO levels (2111 ± 139 μmol/36 h) compared with equivalent-aged men (1682 ± 87 μmol/36 h).
Furthermore, urinary 15 N nitrate production by NO synthase over the course of 36 hours was positively associated with serum 7β-estradiol levels in females, suggesting a strong link between estrogen levels and NO synthase activity. 22 3. Sex differences in superoxide production and renal function Although men exhibit more rapid declines in renal function than women, the mechanisms underlying this sex difference have not been clearly demonstrated. Estrogens have protective effects on kidney-related diseases by attenuating kidney injuries induced by superoxide production, whereas testosterone inhibits antioxidant enzymes. 25 Ji et al. 25 A study of 1,518 postmenopausal women reported a higher prevalence of microalbuminuria in HRT users (14.2%) than nonusers (11.6%) in women with >5 years of postmenopausal therapy. 30 In contrast, a study by Schopick et al. 31 examining 2,445 nondiabetic women reported that women receiving HRT for >6 years exhibited lower overall urinary albumincreatinine ratios than those not receiving treatment. 31 A third cross-sectional study of 1,044 postmenopausal women found that HRT was associated with better eGFR and BP levels than that of nonusers. Improvements in BP and decreases in urinary albumin excretion were observed during a 10 year follow up from 443 participants; however, there was no association between eGFR and continuous HRT. To test whether these decreases were affected, at least in part, by sex hormones, 36 Hsu et al. 37 examined the effects of testosterone on renal klotho expression. Renal klotho and androgen receptor (AR) mRNAs were increased 3.6-and 3.5-fold, relative to controls after dihydrotestosterone stimulation for 24 hours. Interestingly, klotho expression was not affected by exogenous androgen stimulation, suggesting that renal klotho expression may be regulated by testosterone via an AR-dependent mechanism. In contrast to testosterone, estrogen deficiency increased klotho protein levels in aromatase-deficient mice. 38 While klotho expression was decreased after estradiol therapy in this estrogen deficiency model, the influence of sex-steroid hormones on renal klotho expression have not been confirmed in other animal research or human studies. Although renal klotho expression is affected by other regulators including epidermal growth factor, peroxisome proliferator activated receptor agonists, and tumor necrosis factor-a, the mechanisms underlying these effects are not fully understood.
Conclusion
CKD is a common issue in older individuals and, therefore, a growing problem in aging populations, such as that seen in Korea. CKD incidence and disease pathology progresses in accordance with age and menopausal status due to the decrease in naturally occuring estrogen production.
Estrogen has been shown to confer protection against CKD and diminished renal function via several mechanisms, in- 
